Learn more

HANALL BIOPHARMA CO LTD

Overview
  • Total Patents
    179
  • GoodIP Patent Rank
    48,735
  • Filing trend
    0.0%
About

HANALL BIOPHARMA CO LTD has a total of 179 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2005. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are SILANES SA DE CV LAB, SHERING AKTSIENGEZEL SHAFT and CELLGATE INC.

Patent filings per year

Chart showing HANALL BIOPHARMA CO LTDs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Kim Sung Wuk 131
#2 Jun Sung Soo 92
#3 Koo Ja Seong 63
#4 Jeong Jae Kap 39
#5 Song Yeon Jung 38
#6 Min Chang Hee 37
#7 Kim Yong Eun 37
#8 Park Seung Kook 37
#9 Kim Eun Sun 34
#10 Lee Ji Sun 24

Latest patents

Publication Filing date Title
US2017210805A1 Antibody binding to FcRn for treating autoimmune diseases
TW201714621A Antibody binding to fcrn for treating autoimmune diseases
KR20160141044A Extended Release Formulation for Oral Administration of Sildenafil
KR20160141045A Pharmaceutical composition containing of Bosentan
WO2015167293A1 Antibody binding to fcrn for treating autoimmune diseases
KR20150060099A Pharmaceutical composition comprising n1-cyclic amine-n5-substituted bigunide derivatives as an ingredient for preventing or treating aging-induced cognitive decline
KR20150055986A Extended Release Formulation for Oral Administration of Bosentan
KR20150052419A Biguanide compounds and use thereof
KR20150051016A Guanidine compounds and use thereof
US2014235558A1 Pharmaceutical composition having activity of anticancer
KR20140147606A FcRn specific human antibody and composition for treatment of autoimmune diseases
KR20140137681A Pharmaceutical composition comprising n1-cyclic amine-n5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosis
CN104487057A Bosentan controlled release oral preparation
CN104394881A New uses of modified human tumor necrosis factor receptor-1 polypeptide
KR20140101073A N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
KR20140101074A N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
KR20140096671A Pharmaceutical composition comprising n1-cyclic amine-n5-substituted biguanide derivatives as an ingredient for preventing or treating jet-lag syndrom
US2013071471A1 Pharmaceutical composition for treating atopic dermatitis
WO2013022280A2 N1-cyclic amine-n2-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
KR20130018622A N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same